Showing results (151-160 of 410) with videos related to
Sort By:
Pageof 41
Cancer Research Communications|April 29, 2024
A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal MelanomaElizabeth I Buchbinder, Justine V Cohen, Giuseppe Tarantino, et al.Cancer Immunology Research|March 2, 2017
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer PatientsGuillermo De Velasco, Youjin Je, Dominick Bossé, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2020
Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib StudyJohn W Moroney, John Powderly, Christopher H Lieu, et al.Cancer|August 13, 2015
Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanomaElizabeth I Buchbinder, Jeffrey A Sosman, Donald P Lawrence, et al.Cancer|November 15, 2022
Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical courseAneesha Haryal, Matthew J Townsend, Vinitha Baskaran, et al.JCO Precision Oncology|October 5, 2020
Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint BlockadePeter G Miller, Christopher J Gibson, Arnav Mehta, et al.The Oncologist|May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaRyan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJeffrey S Weber, F Stephen Hodi, Jedd D Wolchok, et al.Journal for Immunotherapy of Cancer|August 18, 2016
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanomaAsim Amin, David H Lawson, April K S Salama, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.Pageof 41